TD Cowen Downgrades Mirati Therapeutics (MRTX) to Market Perform
Tweet
Share
E-mailGet Alerts MRTX Hot Sheet
Price: $58.70 --0%
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
TD Cowen analyst Tyler Van Buren downgraded Mirati Therapeutics (NASDAQ: MRTX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.
Shares of Mirati Therapeutics closed at $57.02 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
